Atypical Hemolytic Uremic Syndrome after SARS-CoV-2 Infection: Report of Two Cases

Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation. Immune activation by viruses, including SARS-CoV-2, can lead to the development of an episode of aHUS against a background of genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Smarz-Widelska, Iwona, Syroka-Główka, Małgorzata, Janowska-Jaremek, Joanna, Kozioł, Małgorzata M., Załuska, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9517572/
https://www.ncbi.nlm.nih.gov/pubmed/36141710
http://dx.doi.org/10.3390/ijerph191811437
Descripción
Sumario:Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disease causing systemic thrombotic microangiopathy (TMA) due to the fact of complement dysregulation. Immune activation by viruses, including SARS-CoV-2, can lead to the development of an episode of aHUS against a background of genetic dysregulation in the complement pathway. This paper presents an analysis of two cases of aHUS—siblings diagnosed with familial disease, with a genetic predisposition to aHUS, in whom infection with SARS-CoV-2 was a strong trigger of disease recurrence. The quick recognition and treatment with eculizumab in the early stage of the disease resulted in a rapid improvement in clinical conditions and laboratory parameters.

Ejemplares similares